CORDIS
EU research results

CORDIS

English EN
PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910

PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910

Objective

Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there has been a rise in pertussis incidence, particularly in vaccinated adolescents and adults in industrialized countries. The increased circulation of B. pertussis (Bp) constitutes a risk for transmission to vulnerable infants and older adults. Additionally, immunity in humans has been shown to wane rapidly after immunization with pertussis vaccines, especially with acellular pertussis (aP) vaccines, suggesting that the improved reactogenicity profile of aP compared to whole cell pertussis vaccines, may be accompanied by differences in duration of immunity. The key objectives of PERISCOPE are to 1. identify biomarkers of protection against Bp colonization and disease; 2. foster scientific innovation and rebuild the ecosystem and technical infrastructure needed in Europe to allow the future evaluation of novel pertussis vaccine candidates and 3. improve understanding of the pathogenesis of Bp infection and its potential impact on the recently observed changes in pertussis epidemiology. To reach these objectives, PERISCOPE brings together a selected group of internationally recognized public and EFPIA partners with strong expertise in clinical trials, immunology, molecular microbiology, human and animal challenge models and bioinformatics. We will initiate a series of (pre)clinical studies and develop harmonized human and animal challenge models, standardized assays and cutting-edge techniques to unravel the innate and adaptive responses to Bp. This will allow us to identify biomarkers of protection and durable immunity. PERISCOPE will thus facilitate the accelerated development and registration of novel pertussis vaccines and/or guide optimal use of vaccination strategies. The introduction of improved pertussis vaccines will help to reduce the global burden of pertussis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING KATHOLIEKE UNIVERSITEIT

Address

Geert Grooteplein Noord 9
6525 Ez Nijmegen

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 701 114,62

Participants (23)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 779 999

Department of Health

United Kingdom

EU Contribution

€ 564 110

INSTITUT PASTEUR DE LILLE FONDATION

France

EU Contribution

€ 799 998

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 650 000

TURUN YLIOPISTO

Finland

EU Contribution

€ 1 475 000

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 1 500 243

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 84 380,69

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Netherlands

EU Contribution

€ 2 021 832

MIKROBIOLOGICKY USTAV - AVCR, V.V.I.

Czechia

EU Contribution

€ 300 000

UNIVERSITAT BASEL

Switzerland

UNIVERSITY OF BATH

United Kingdom

EU Contribution

€ 399 455

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 1 492 500

UNIVERSIDAD DE SALAMANCA

Spain

EU Contribution

€ 547 500

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 299 995

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 2 561 944

Q-BIOLOGICALS NV

Belgium

EU Contribution

€ 175 097

UNITED KINGDOM RESEARCH AND INNOVATION

United Kingdom

EU Contribution

€ 67 125,75

MEDICAL RESEARCH COUNCIL

United Kingdom

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 531 250

SANOFI PASTEUR SA

France

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 2 048 455,94

Project information

Grant agreement ID: 115910

Status

Ongoing project

  • Start date

    1 March 2016

  • End date

    28 February 2021

Funded under:

H2020-EU.3.1.7.12.

  • Overall budget:

    € 29 926 682

  • EU contribution

    € 21 000 000

Coordinated by:

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands